» Articles » PMID: 15847994

In Vitro Characterization of Some Biopharmaceutical Properties of Praziquantel

Overview
Journal Int J Pharm
Specialties Chemistry
Pharmacology
Date 2005 Apr 26
PMID 15847994
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

In several studies of patients with neurocysticercosis under treatment with praziquantel (PZQ), the pharmacokinetic data were difficult to interpret probably because of the low solubility as well as its variable oral bioavailability. Because there is limited information available regarding the biopharmaceutical properties of PZQ, the aim of this work was to evaluate the absorption characteristics of the drug and its dissolution behaviour in simulated media. Additionally, its in vitro protein binding and displacement by highly bound drugs was evaluated. Permeability evaluation was carried out by using Caco-2 cells. Dissolution release profiles were evaluated using the USP apparatus and the following dissolution media: HCl containing 2mg of sodium laurylsulfate per milliliter, milk, FeSSIF and FaSSIF. Protein binding of PZQ was carried out by equilibrium dialysis. Results showed that praziquantel was absorbed by passive diffusion. The apparent permeability constant value was 4.4x10(-5) cm/s. Binding was not influenced by the addition of highly bound drugs. Dissolution from a tablet formulation showed that the rate of praziquantel was dependent on the components of the media. Although the simulated media could explain the influence of the lipids on praziquantel absorption, they were not able to forecast the influence of carbohydrates. Further refinements are required to explain the in vivo data.

Citing Articles

-Schistosomal activity and ADMET properties of 1,2,5-oxadiazinane-containing compound synthesized by visible-light photoredox catalysis.

Itoh K, Nakahara H, Takashino A, Hara A, Katsuno A, Abe Y RSC Med Chem. 2024; .

PMID: 39399310 PMC: 11467761. DOI: 10.1039/d4md00599f.


Amorphous Solid Dispersion Formation for Enhanced Release Performance of Racemic and Enantiopure Praziquantel.

Polyzois H, Nguyen H, Roberto de Alvarenga Junior B, Taylor L Mol Pharm. 2024; 21(10):5285-5296.

PMID: 39292641 PMC: 11462518. DOI: 10.1021/acs.molpharmaceut.4c00711.


Praziquantel Fifty Years on: A Comprehensive Overview of Its Solid State.

DAbbrunzo I, Procida G, Perissutti B Pharmaceutics. 2024; 16(1).

PMID: 38258039 PMC: 10821272. DOI: 10.3390/pharmaceutics16010027.


Preformulation and Long-Term Stability Studies of an Optimized Palatable Praziquantel Ethanol-Free Solution for Pediatric Delivery.

Bedogni G, Garcia P, Seremeta K, Okulik N, Salomon C Pharmaceutics. 2023; 15(8).

PMID: 37631264 PMC: 10458622. DOI: 10.3390/pharmaceutics15082050.


Revisiting the Dissolution of Praziquantel in Biorelevant Media and the Impact of Digestion of Milk on Drug Dissolution.

Eason T, Ramirez G, Clulow A, Salim M, Boyd B Pharmaceutics. 2022; 14(10).

PMID: 36297662 PMC: 9609124. DOI: 10.3390/pharmaceutics14102228.